Ampira Biotechnics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-07-2024
- Paid Up Capital ₹ 0.10 M
as on 16-07-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 16-07-2024
- Revenue -35.92%
(FY 2023)
- Profit -40.01%
(FY 2023)
- Ebitda -13.12%
(FY 2023)
- Net Worth 41.38%
(FY 2023)
- Total Assets 18.02%
(FY 2023)
About Ampira Biotechnics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Babita, Ajay, and Satwant Singh serve as directors at the Company.
- CIN/LLPIN
U24239CH2019PTC042374
- Company No.
042374
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Manimajra, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ampira Biotechnics Private Limited offer?
Ampira Biotechnics Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Pharmaceutical Capsules, Nutraceuticals & Dietary Supplements, Mineral Supplement, Sexual Wellness Products, Fertility Enhancer, Fitness Supplements, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Ampira Biotechnics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babita  | Director | 12-Feb-2019 | Current |
| Ajay | Director | 12-Feb-2019 | Current |
| Satwant Singh | Director | 12-Feb-2019 | Current |
Financial Performance of Ampira Biotechnics.
Ampira Biotechnics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 35.92% decrease. The company also saw a substantial fall in profitability, with a 40.01% decrease in profit. The company's net worth Soared by an impressive increase of 41.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ampira Biotechnics?
In 2023, Ampira Biotechnics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Grapple Lifesciences Private LimitedActive 13 years 1 monthAjay and Satwant Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Jun 2023 | ₹5.00 M | Open |
How Many Employees Work at Ampira Biotechnics?
Unlock and access historical data on people associated with Ampira Biotechnics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ampira Biotechnics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ampira Biotechnics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
